Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
153 hedge funds and large institutions have $337M invested in Eagle Pharmaceuticals, Inc. in 2022 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 63 increasing their positions, 47 reducing their positions, and 32 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 47
6% less funds holding
Funds holding: 163 → 153 (-10)
28% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 32
34% less capital invested
Capital invested by funds: $509M → $337M (-$173M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$38.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$8.66M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$4.56M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$4.39M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
+$4.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.51M |
| 2 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$4.4M |
| 3 |
FP
Foundry Partners
Minneapolis,
Minnesota
|
-$3.75M |
| 4 |
GC
Globeflex Capital
San Diego,
California
|
-$3.25M |
| 5 |
BlackRock
New York
|
-$2.73M |
EGRX Hedge Fund Activity: Q3 2022 in Review
153 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q3 2022, worth a combined $337M — down 34% from $509M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of EGRX and 23 opened new positions — a net loss of 9 holders — while 47 trimmed existing stakes and 63 added.
The largest buyer was Janus Henderson Group, adding an estimated $38.2M. The largest seller was Millennium Management, cutting an estimated $5.51M.
- 153 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q3 2022, down from 163 in Q2 2022.
- Funds reported $337M of Eagle Pharmaceuticals, Inc. stock for Q3 2022, down 34% quarter-over-quarter.
- 23 funds opened new Eagle Pharmaceuticals, Inc. positions in Q3 2022 and 32 closed out, a net change of -9 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q3 2022 was Janus Henderson Group, an estimated $38.2M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q3 2022 was Millennium Management, an estimated $5.51M sold.
Based on aggregated 13F filings for Q3 2022.